Sciencast Management LP Reduces Stake in Johnson & Johnson (JNJ)

Share on StockTwits

Sciencast Management LP lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 62.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 4,365 shares of the company’s stock after selling 7,188 shares during the period. Sciencast Management LP’s holdings in Johnson & Johnson were worth $570,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Goodman Financial Corp bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $104,000. Stelac Advisory Services LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $108,000. Princeton Capital Management LLC bought a new position in Johnson & Johnson in the 1st quarter worth about $141,000. Smart Portfolios LLC bought a new position in Johnson & Johnson in the 1st quarter worth about $150,000. Finally, Wrapmanager Inc. bought a new position in Johnson & Johnson in the 4th quarter worth about $213,000. Hedge funds and other institutional investors own 71.53% of the company’s stock.

JNJ opened at $137.32 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The stock has a market cap of $364.50 billion, a price-to-earnings ratio of 18.81, a P/E/G ratio of 2.07 and a beta of 0.69. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. The business had revenue of $20.83 billion for the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.83 EPS. analysts expect that Johnson & Johnson will post 8.14 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.62%. The ex-dividend date is Monday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

A number of brokerages recently issued reports on JNJ. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target on the stock. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b” rating in a research note on Friday, May 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $142.34.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.22% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Return on Investment (ROI)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply